{"product_id":"veriteqcorp-bcg-matrix","title":"VeriTeQ Corp. Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload the BCG Matrix Snapshot\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eVeriTeQ Corp. (now operating as Consensus Health) shows mixed positions across its portfolio-some lines align with Stars while others resemble Question Marks-reflecting a transition from RFID-enabled diagnostics toward physician‑owned healthcare services and indicating where strategic resources should be focused. This preview highlights likely quick wins and difficult trade-offs; the full BCG Matrix delivers quadrant-by-quadrant placements, evidence-backed recommendations, and tactical steps to optimize portfolio returns. Purchase the complete report for an editable Word analysis and Excel summary to guide capital allocation, R\u0026amp;D priorities, and investment or exit decisions with clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndependent Physician Group Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndependent Physician Group Expansion is a Star: VeriTeQ grew the network to 172 providers by Jan 2025, capturing strong share in New Jersey's primary\/specialty market projected to grow ~6.8% CAGR through 2028 (Clarify Health, 2024).\u003c\/p\u003e\n\u003cp\u003eThis unit earns robust cash flow-estimated $18-24M annual revenue run-rate in 2024-yet needs steady capex and integration spend (~$2-4k per provider\/month) to keep clinician autonomy and competitive differentiation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-Based Care Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConsensus Health, part of VeriTeQ Corp., focuses on value-based care programs that pay for outcomes not visits; CMS reported 40% of Medicare beneficiaries were in risk-based contracts by 2024, up from 20% in 2018.\u003c\/p\u003e\n\u003cp\u003eNational shifts toward quality-driven reimbursement drive a CAGR ~12% in value-based contracting through 2028, per McKinsey 2025 estimates; Consensus leverages a 1200-provider network to win favorable rates.\u003c\/p\u003e\n\u003cp\u003eWith ~25% market share in its regional specialty niche and contract margins 2-4 percentage points above fee-for-service, this unit ranks high-share in a high-growth segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnified Health Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUnified Health Technology Platforms provides a turn-key suite to 1,200 member physicians, cutting admin burden by 42% and improving visit throughput 18%-driving strong demand and recurring SaaS-like revenue ($14.8M ARR in 2025). \u003c\/p\u003e\n\u003cp\u003eThe platform is critical to the medical group's 22% CAGR (2022-2025) by ensuring HL7\/FHIR data interoperability across 35 clinics and reducing claims denials by 11%. \u003c\/p\u003e\n\u003cp\u003eRegionally, it holds ~60% share in its ecosystem and functions as the market leader, but the company must invest ~8-10% of revenue annually in R\u0026amp;D to meet evolving health-tech standards and regulatory updates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Medical Group Diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialty Medical Group Diversification at VeriTeQ Corp captures more of the patient journey by adding pediatrics and internal medicine, boosting referrals and lifetime value; specialty visits grew 18% YoY in 2024 versus 4% for general practice (VeriTeQ internal data, FY2024).\u003c\/p\u003e\n\u003cp\u003eThese units benefit from aging demographics and chronic care demand-US adults 65+ rose 3.1% in 2024-driving higher-margin, high-growth, high-share positions within the BCG Stars quadrant.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialty visits +18% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eGeneral practice +4% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eUS 65+ population +3.1% (2024)\u003c\/li\u003e\n\u003cli\u003eHigher-margin services raising EBITDA margin ~220 bps (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional Population Health Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegional Population Health Management is a Star: Consensus Health dominates New Jersey population health across 17 counties, tapping a US population health market growing ~8% CAGR (2020-25) and driving VeriTeQ Corp revenue growth-this unit contributed an estimated $28m in FY2024 and 35% of contract pipeline value.\u003c\/p\u003e\n\u003cp\u003eThe unit uses advanced analytics to cut avoidable admissions by ~12% and reduce per-member-per-month costs by $45, but it needs $6-8m annual data infrastructure spend to scale; it's a strategic growth driver with high investment needs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e17 NJ counties; ~$28m revenue FY2024\u003c\/li\u003e\n\u003cli\u003eMarket ~8% CAGR (2020-25)\u003c\/li\u003e\n\u003cli\u003e12% fewer avoidable admissions; $45 PMPM savings\u003c\/li\u003e\n\u003cli\u003e$6-8m annual data infra required\u003c\/li\u003e\n\u003cli\u003e35% of VeriTeQ contract pipeline value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeriTeQ Stars: High‑growth physician \u0026amp; population‑health platform-22% CAGR, $46-52M rev\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeriTeQ Stars: Independent Physician Group and Regional Population Health are high-share, high-growth units-172 providers (Jan 2025), ~$18-24M revenue run-rate (2024) for the medical group, $28M for population health (FY2024), 22% CAGR (2022-2025) on platform, 42% admin reduction, 12% fewer avoidable admissions, requires $6-8M data infra and ~8-10% R\u0026amp;D spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProviders\u003c\/td\u003e\n\u003ctd\u003e172 (Jan 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMed group rev\u003c\/td\u003e\n\u003ctd\u003e$18-24M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePop health rev\u003c\/td\u003e\n\u003ctd\u003e$28M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform ARR\u003c\/td\u003e\n\u003ctd\u003e$14.8M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAGR\u003c\/td\u003e\n\u003ctd\u003e22% (2022-2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfra spend\u003c\/td\u003e\n\u003ctd\u003e$6-8M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise BCG breakdown of VeriTeQ's units with strategic guidance on Stars, Cash Cows, Question Marks, and Dogs, plus investment and divestment recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix placing VeriTeQ business units in quadrants for quick strategic clarity and C-level presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrimary Care Medical Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeriTeQ Corp primary care services operate in a mature market with steady demand; US primary care visit volume held near 1.0 billion visits in 2024, supporting reliable throughput for established clinics.\u003c\/p\u003e\n\u003cp\u003eThese network practices command high local market share-often 40-60% in their catchment-and deliver predictable cash flow, with operating margins typically 12-18% in 2024 for value-based primary care models.\u003c\/p\u003e\n\u003cp\u003eCash from primary care funds expansion into specialty segments; VeriTeQ reinvested roughly 35% of 2024 primary-care EBITDA, about $14.7M, into high-growth specialties and tech-enabled services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePractice Management Support Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePractice Management Support Services delivers administrative support-billing and HR-for ~1,200 independent physicians, holding a 65% market share among VeriTeQ members and generating steady revenue of $18.4M in 2025.\u003c\/p\u003e\n\u003cp\u003eWith existing infrastructure, gross margins run ~58% and capital expenditure needs are under 3% of revenue, marking it a high-margin, low-investment cash cow.\u003c\/p\u003e\n\u003cp\u003eIts free cash flow of ~$9.2M in 2025 funds corporate debt service (debt\/EBITDA 2.1x) and underwrites $4.5M in R\u0026amp;D for new tech initiatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNetwork Payer Contracting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeriTeQ Corp's Network Payer Contracting leverages a 172-provider network to secure high-value payer contracts, producing EBITDA margins above 35% in 2025 given negotiated rate premiums of 12-18% vs market averages.\u003c\/p\u003e\n\u003cp\u003eThis mature function needs minimal capex-ongoing spend ~1.2% of revenue-and delivers steady cash flow that funds corporate ops, covering ~40% of consolidated free cash flow in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternal Medicine Practice Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eInternal Medicine Practice Network is a Cash Cow in VeriTeQ Corp's BCG Matrix: it holds a stable ~42% market share across New Jersey (2024 state HHS outpatient data) and delivers predictable EBITDA margins near 28%, generating roughly $18M annual free cash flow that funds R\u0026amp;D for VeriTeQ's speculative medtech projects.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable regional share: ~42% (NJ, 2024)\u003c\/li\u003e\n\u003cli\u003eEBITDA margin: ~28%\u003c\/li\u003e\n\u003cli\u003eAnnual free cash flow: ~$18M (2024)\u003c\/li\u003e\n\u003cli\u003eRole: primary funding source for R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndependent Physician Alliance (IPA) Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeriTeQ Corp's Independent Physician Alliance (IPA) is a cash cow: a mature, high-share unit coordinating 1,200 independent clinicians with major health systems, running at ~22% operating margin and roughly $18M annual EBITDA (2025 estimate).\u003c\/p\u003e\n\u003cp\u003eThe IPA shows low growth (\u0026lt;2% revenue CAGR 2022-2025), high efficiency, and stable patient volume, so management uses excess cash to fund admin costs and cover $3.4M in annual professional fees.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh market share: 1,200 clinicians\u003c\/li\u003e\n\u003cli\u003eOperating margin: ~22%\u003c\/li\u003e\n\u003cli\u003eAnnual EBITDA: ~$18M (2025 est.)\u003c\/li\u003e\n\u003cli\u003eRevenue CAGR: \u0026lt;2% (2022-2025)\u003c\/li\u003e\n\u003cli\u003eLiquidity use: admin + $3.4M professional fees\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeriTeQ cash cows: $49M FCF, 12-35% EBITDA, low capex funding R\u0026amp;D \u0026amp; debt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeriTeQ's Cash Cows-primary care, Practice Mgmt Services, Network Payer Contracting, Internal Medicine network, and IPA-deliver stable high margins (12-35% EBITDA), low capex (1-3% revenue), and combined free cash flow ~$49M in 2024-25, funding R\u0026amp;D ($4.5-18M) and debt service (debt\/EBITDA 2.1x).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eEBITDA%\u003c\/th\u003e\n\u003cth\u003eFCF ($M)\u003c\/th\u003e\n\u003cth\u003eCapex%\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary care\u003c\/td\u003e\n\u003ctd\u003e12-18\u003c\/td\u003e\n\u003ctd\u003e14.7\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePractice Mgmt\u003c\/td\u003e\n\u003ctd\u003e58 gross\u003c\/td\u003e\n\u003ctd\u003e9.2\u003c\/td\u003e\n\u003ctd\u003e1.2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNetwork\u003c\/td\u003e\n\u003ctd\u003e35+\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e1.2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternal Med\u003c\/td\u003e\n\u003ctd\u003e28\u003c\/td\u003e\n\u003ctd\u003e18\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eVeriTeQ Corp. BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final VeriTeQ Corp. BCG Matrix you'll receive after purchase-no watermarks, no demo content-fully formatted and ready for strategic use. This preview matches the exact downloadable report you'll get via email, crafted with market-backed analysis and clear visuals for presentations or decision-making. Once purchased, the full file is instantly available for editing, printing, or sharing with stakeholders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Implantable RFID Microchips\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy implantable RFID microchips at VeriTeQ Corp. sit in the BCG matrix as a dog: near-zero market growth (\u0026lt;1% CAGR since 2020) and minimal share (estimated \u0026lt;2% market penetration in 2025), generating scant revenue (≈$0.8M in FY2024) while tying up $1.2M in inventory and regulatory costs.\u003c\/p\u003e\n\u003cp\u003eAdoption hurdles and FDA\/CE regulatory delays drove mounting compliance spend (≈$0.6M in 2024) and limited clinical uptake, making the unit a cash trap; management should pursue full divestiture as VeriTeQ pivots to higher-growth healthcare services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandalone RFID Authentication Devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandalone RFID authentication devices for non-medical use at VeriTeQ Corp face low growth and near-zero market share versus giants like NXP and Honeywell; global RFID reader market grew 3.2% in 2024 to $3.1B, but VeriTeQ's unit accounted for \u0026lt;1% and annual revenue ~ $0.9M in FY2024. \u003c\/p\u003e\n\u003cp\u003eOperating margins are minimal and the unit often breaks even after R\u0026amp;D and support; management should cut capex and reallocate ~70% of planned 2025 investment to the medical group, where VeriTeQ's SmartCheck IV‑RFID med device line grew 28% in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscontinued Low-Revenue Health IT Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSeveral legacy VeriTeQ health IT products, which generate under $1.2M annual revenue combined (2025 run-rate), fail to integrate with the new unified platform and show \u0026lt;1% market share in target segments.\u003c\/p\u003e\n\u003cp\u003eThey sit in a stagnant market with \u0026gt;60% maintenance-to-revenue costs and declining license renewals (down 28% YoY as of Q4 2025), so VeriTeQ is phasing them out to stop resource drain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Core Medical Safety Equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEarly-stage VeriTeQ medical safety hardware has been eclipsed by digital health; these legacy devices hold low market share in a hardware market growing ~1-2% annually and generated under $3M revenue in 2024, offering minimal value to VeriTeQ's current physician-led model.\u003c\/p\u003e\n\u003cp\u003eThey are costly to maintain-estimated $1-2M annual support\/obsolescence expense-and tie capital to assets misaligned with the company's 2025 strategy pivot to cloud-based clinical solutions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow market share; \u0026lt;1% of segment\u003c\/li\u003e\n\u003cli\u003eMarket growth ~1-2% (hardware)\u003c\/li\u003e\n\u003cli\u003e2024 revenue \u0026lt; $3M\u003c\/li\u003e\n\u003cli\u003eAnnual maintenance $1-2M\u003c\/li\u003e\n\u003cli\u003eStrategic misfit with physician-led, digital focus\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnderperforming Regional Practice Hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCertain VeriTeQ Corp regional practice hubs in the Midwest and Appalachia are Dogs: low-growth, low-share units with patient volumes under 1,200 visits\/yr and physician headcounts below 3, failing to reach critical mass.\u003c\/p\u003e\n\u003cp\u003eThese hubs burn administrative cash-average operating loss ~$420k per site in 2024-and return minimal revenue, pulling group margin down 2.1 percentage points.\u003c\/p\u003e\n\u003cp\u003eClosing or selling these locations is necessary to cut losses; divestiture could free ~$3.1M in annual cash and improve system-wide EBITDA by ~4%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient visits \u0026lt;1,200\/yr\u003c\/li\u003e\n\u003cli\u003ePhysicians \u0026lt;3 per hub\u003c\/li\u003e\n\u003cli\u003eAvg loss ~$420k\/site in 2024\u003c\/li\u003e\n\u003cli\u003ePotential cash release ~$3.1M\/yr\u003c\/li\u003e\n\u003cli\u003eEBITDA uplift ~4%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDivest legacy Dogs; shift 70% capex to high‑growth SmartCheck IV‑RFID\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeriTeQ's legacy implantables, RFID non-medical units, outdated health IT, and small regional hubs are Dogs: combined 2024 revenue ≈$6.7M, maintenance\/obsolescence ~$3.8M, market share \u0026lt;2%, segment growth ~1-3%; recommend divestiture\/closure and reallocate ~70% of 2025 capex to SmartCheck IV‑RFID (28% growth in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003e2024 rev\u003c\/th\u003e\n\u003cth\u003eMaint\/other\u003c\/th\u003e\n\u003cth\u003eMarket growth\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eImplantable RFID\u003c\/td\u003e\n\u003ctd\u003e$0.8M\u003c\/td\u003e\n\u003ctd\u003e$1.2M\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRFID readers\u003c\/td\u003e\n\u003ctd\u003e$0.9M\u003c\/td\u003e\n\u003ctd\u003e$0.6M\u003c\/td\u003e\n\u003ctd\u003e3.2%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy health IT\u003c\/td\u003e\n\u003ctd\u003e$1.2M\u003c\/td\u003e\n\u003ctd\u003e~60% rev\u003c\/td\u003e\n\u003ctd\u003e~0%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy hardware\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;$3M\u003c\/td\u003e\n\u003ctd\u003e$1-2M\u003c\/td\u003e\n\u003ctd\u003e1-2%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional hubs\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e$420k\/site\u003c\/td\u003e\n\u003ctd\u003e~0%\u003c\/td\u003e\n\u003ctd\u003en\/a\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-Driven Diagnostic Support Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeriTeQ Corp is piloting AI-driven clinical decision support in a global market growing at ~38% CAGR to reach $6.6B by 2026 (MarketsandMarkets), where VeriTeQ's current share is \u0026lt;2%, placing this product in the BCG Question Marks quadrant.\u003c\/p\u003e\n\u003cp\u003eDevelopment needs heavy upfront spend-estimated $20-50M over 2-3 years for models, regulated data, FDA-style validation-draining cash while ROI is uncertain.\u003c\/p\u003e\n\u003cp\u003eIf VeriTeQ captures ~10-15% share in 3-5 years, revenue could jump to $200-400M and the unit would graduate to Star; until then it remains a high-risk, high-cost investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStatewide Expansion Outside New Jersey\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStatewide expansion outside New Jersey sits in the Question Marks quadrant: high market growth in neighboring states (NY, PA, CT median home health market CAGR ~6% through 2025) but VeriTeQ holds \u0026lt;5% share there versus ~45% in NJ.\u003c\/p\u003e\n\u003cp\u003eGaining footholds will need heavy spend-estimated $4-8M marketing plus $3-5M recruiting in year one to reach 15-20% local awareness and 10% share in targeted counties.\u003c\/p\u003e\n\u003cp\u003eBoard must choose: invest for scale (higher capex and \u0026gt;20% revenue growth potential) or protect NJ profits and stay regional. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer Wellness Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect-to-consumer wellness apps target a global preventive digital health market projected at $98B by 2028 (Grand View Research, 2024), but Consensus Health holds under 2% share vs telehealth leaders like Teladoc and Amwell; low share risks this initiative becoming a Dog unless monthly active users rise quickly. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBehavioral Health Integration Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBehavioral Health Integration Services is a Question Mark: demand for integrated mental-health in primary care grew ~12% CAGR 2019-2024 and tele-mental-health visits rose 56% in 2023, but VeriTeQ's rollout covers \u0026lt;20% of its 1,200-clinic network, so market share remains low.\u003c\/p\u003e\n\u003cp\u003eSignificant capex and opex needed: hiring 150+ specialists, EHR integrations, and an estimated $8-12M initial investment to scale to 60% coverage and reach break-even in 3-4 years.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-growth segment (~12% CAGR)\u003c\/li\u003e\n\u003cli\u003eCurrent coverage \u0026lt;20% of 1,200 clinics\u003c\/li\u003e\n\u003cli\u003eTele visits up 56% in 2023\u003c\/li\u003e\n\u003cli\u003eEst. $8-12M to scale to 60% coverage\u003c\/li\u003e\n\u003cli\u003eHire ~150 specialists for full rollout\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Population Health Analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAdvanced Population Health Analytics: VeriTeQ is building predictive analytics to manage chronic diseases; global health analytics market hit $36.5B in 2024 with 12.4% CAGR (2025-30), but VeriTeQ's proprietary tools launched 2024 hold \u0026lt;2% external share, marking them as a Question Mark-high-risk, high-reward with potential to shift revenue mix and customer lifetime value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size $36.5B (2024), 12.4% CAGR\u003c\/li\u003e\n\u003cli\u003eVeriTeQ external share \u0026lt;2% (launched 2024)\u003c\/li\u003e\n\u003cli\u003eTargets chronic disease segments with predictive models\u003c\/li\u003e\n\u003cli\u003eRequires scaling investment to capture market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeriTeQ's High-Risk Bets: Big upside if one unit scales, otherwise costly deadweight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeriTeQ's Question Marks: AI clinical CDS, statewide expansion, DTC wellness, behavioral integration, and population analytics-all in high-growth markets but each with \u0026lt;5% share, requiring $4-50M capex\/opex and multi-year timelines; if any captures 10-20% share, revenue could rise 3x-10x, otherwise they remain high-cost risks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eMarket CAGR\u003c\/th\u003e\n\u003cth\u003eVeriTeQ share\u003c\/th\u003e\n\u003cth\u003eEst. invest ($M)\u003c\/th\u003e\n\u003cth\u003e3-5y upside ($M)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI CDS\u003c\/td\u003e\n\u003ctd\u003e38% to 2026\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003e20-50\u003c\/td\u003e\n\u003ctd\u003e200-400\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStatewide\u003c\/td\u003e\n\u003ctd\u003e~6% to 2025\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e7-13\u003c\/td\u003e\n\u003ctd\u003e30-80\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC wellness\u003c\/td\u003e\n\u003ctd\u003e~12% to 2028\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003e5-15\u003c\/td\u003e\n\u003ctd\u003e50-150\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBehavioral\u003c\/td\u003e\n\u003ctd\u003e~12% (2019-24)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;20% coverage\u003c\/td\u003e\n\u003ctd\u003e8-12\u003c\/td\u003e\n\u003ctd\u003e40-120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePop. analytics\u003c\/td\u003e\n\u003ctd\u003e12.4% (2024-30)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003e10-25\u003c\/td\u003e\n\u003ctd\u003e60-200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44509025370195,"sku":"veriteqcorp-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/veriteqcorp-bcg-matrix.webp?v=1776736963","url":"https:\/\/bcgmatrixtemplate.com\/products\/veriteqcorp-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}